The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved Eylea 8 mg (aflibercept 8 mg) for the treatment of neovascular (wet) age-related macular ...

Bayer said in a statement the European Medicines Agency recommended that eye drug Eylea, at a high dose of 8 mg, can be injected at intervals of up to six months to treat wet age-related macular ...

CEO Leonard Schleifer specifically cited a funding gap at patient assistance foundations as a catalyst for more patients and physicians turning to off-label Avastin over EYLEA, resulting in a ...

A printable version of the full schedule is available at the link below. Buffalo Bills printable 2025 schedule NFL DRAFT GRADES: Recap all NFL Draft picks, grades and analysis for all 32 teams.

Bayer A.G. (OTCPK:BAYZF) (OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the label expansion of a high-dose version of its ophthalmic drug, Eylea ...

boosted by strong demand for a new formulation of its blockbuster eye drug Eylea. The company also announced a new quarterly cash dividend and boosted its share-buyback program by $3 billion ...

The company’s product portfolio is anchored by Eylea, used in treating various eye diseases, and Dupixent, which has shown significant growth potential across multiple indications. In the first ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), a leading biopharmaceutical company with a market capitalization of $62.17 billion, finds itself at a critical juncture as it navigates challenges to its ...

To print, click the 'pop out' button in the top right corner, then use the printer button on the new tab. Note: If it is cutting off the right side of the sheet, go to 'more settings' on the print ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

However, Meacham suggests that the market’s expectations for Eylea in 2026 and 2027 are now more reasonable, with anticipated year-over-year decreases of 10% and 6%, respectively.